A detailed history of Bouvel Investment Partners, LLC transactions in Cerus Corp stock. As of the latest transaction made, Bouvel Investment Partners, LLC holds 505,020 shares of CERS stock, worth $909,036. This represents 0.36% of its overall portfolio holdings.

Number of Shares
505,020
Previous 269,938 87.09%
Holding current value
$909,036
Previous $469,000 87.21%
% of portfolio
0.36%
Previous 0.19%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$1.7 - $2.39 $399,639 - $561,845
235,082 Added 87.09%
505,020 $878,000
Q2 2024

Jul 12, 2024

BUY
$1.62 - $2.04 $144 - $181
89 Added 0.03%
269,938 $475,000
Q1 2024

Apr 15, 2024

BUY
$1.66 - $2.42 $20,291 - $29,582
12,224 Added 4.74%
269,849 $510,000
Q4 2023

Jan 11, 2024

BUY
$1.25 - $2.35 $7,222 - $13,578
5,778 Added 2.29%
257,625 $556,000
Q3 2023

Oct 10, 2023

BUY
$1.5 - $3.07 $7,495 - $15,340
4,997 Added 2.02%
251,847 $407,000
Q2 2023

Jul 14, 2023

BUY
$1.79 - $2.9 $22,931 - $37,151
12,811 Added 5.47%
246,850 $607,000
Q1 2023

Apr 11, 2023

BUY
$2.65 - $3.81 $24,181 - $34,766
9,125 Added 4.06%
234,039 $695,000
Q4 2022

Jan 18, 2023

BUY
$3.38 - $4.22 $28,527 - $35,616
8,440 Added 3.9%
224,914 $0
Q3 2022

Oct 13, 2022

BUY
$3.43 - $5.83 $6,760 - $11,490
1,971 Added 0.92%
216,474 $779,000
Q2 2022

Jul 13, 2022

BUY
$4.41 - $5.69 $13,265 - $17,115
3,008 Added 1.42%
214,503 $1.14 Million
Q1 2022

Apr 11, 2022

BUY
$4.81 - $6.99 $2,626 - $3,816
546 Added 0.26%
211,495 $1.16 Million
Q4 2021

Jan 19, 2022

SELL
$5.97 - $7.93 $20,942 - $27,818
-3,508 Reduced 1.64%
210,949 $1.44 Million
Q3 2021

Oct 07, 2021

BUY
$4.79 - $6.68 $1.03 Million - $1.43 Million
214,457 New
214,457 $1.31 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $319M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Bouvel Investment Partners, LLC Portfolio

Follow Bouvel Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bouvel Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bouvel Investment Partners, LLC with notifications on news.